|
Post by HeyNow on Jul 11, 2014 15:12:25 GMT
This company has $75 million in assets (including almost $70 million in cash and investments), a partnership with Genentech on two of their compounds, and multiple ongoing early phase trials. One compound Genentech licensed from them in Phase 1 in 2003 and brought all the way to market (Erivedge). Curis had a single digit royalty stream on that that it basically sold in a debt financing deal to get non-dilutive cash upfront. The other Curis licensed from Genentech and ownes >90% of the future royalties.
I owned this company before and leading up to FDA approval of Erivedge, then got out. It has come way back down to earth and especially was hit hard when one of their phase 1 trials was halted briefly. That trial is back up and running now. There are also some power players on the board of this company.
With zero dilutive funding on the horizon, a history of successful drug development to market (Erivedge), a powerful partner on multiple drugs in the pipeline, and several early stage trials with some positive results already reported, including some unconfirmed complete responses, and the fact that its stock price has been hammered in the last year: this is an intriguing company.
I'm waiting for some funds to settle then placing a limit order.
|
|
|
Post by selluwud on Jul 11, 2014 15:19:41 GMT
This company has $75 million in assets (including almost $70 million in cash and investments), a partnership with Genentech on two of their compounds, and multiple ongoing early phase trials. One compound Genentech licensed from them in Phase 1 in 2003 and brought all the way to market (Erivedge). Curis had a single digit royalty stream on that that it basically sold in a debt financing deal to get non-dilutive cash upfront. The other Curis licensed from Genentech and ownes >90% of the future royalties. I owned this company before and leading up to FDA approval of Erivedge, then got out. It has come way back down to earth and especially was hit hard when one of their phase 1 trials was halted briefly. That trial is back up and running now. There are also some power players on the board of this company. With zero dilutive funding on the horizon, a history of successful drug development to market (Erivedge), a powerful partner on multiple drugs in the pipeline, and several early stage trials with some positive results already reported, including some unconfirmed complete responses, and the fact that its stock price has been hammered in the last year: this is an intriguing company. I'm waiting for some funds to settle then placing a limit order. What's your projected entry point HeyNow, or in what range?
|
|
|
Post by HeyNow on Jul 11, 2014 15:50:52 GMT
I'm going to buy at current levels, I'll probably place an initial limit order at 1.70. This won't be for a quick trade but rather I think with the stability of the company and their cash and assets, sustained progress in their trials could create a steady appreciation in share price in the next year or so.
|
|
|
Post by JHam on Jul 13, 2014 15:32:35 GMT
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company’s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).
|
|
|
Post by HeyNow on Jul 14, 2014 0:02:35 GMT
This company has $75 million in assets (including almost $70 million in cash and investments), a partnership with Genentech on two of their compounds, and multiple ongoing early phase trials. One compound Genentech licensed from them in Phase 1 in 2003 and brought all the way to market (Erivedge). Curis had a single digit royalty stream on that that it basically sold in a debt financing deal to get non-dilutive cash upfront. The other Curis licensed from Genentech and ownes >90% of the future royalties.
I owned this company before and leading up to FDA approval of Erivedge, then got out. It has come way back down to earth and especially was hit hard when one of their phase 1 trials was halted briefly. That trial is back up and running now. There are also some power players on the board of this company.
With zero dilutive funding on the horizon, a history of successful drug development to market (Erivedge), a powerful partner on multiple drugs in the pipeline, and several early stage trials with some positive results already reported, including some unconfirmed complete responses, and the fact that its stock price has been hammered in the last year: this is an intriguing company.
I'm waiting for some funds to settle then placing a limit order.
|
|
|
Post by JHam on Jul 14, 2014 2:49:31 GMT
HeyNow,
Thank for the rundown. Why was their trial halted? What would be the next big event to be a potential pps mover?
|
|
|
Post by HeyNow on Jul 14, 2014 3:45:47 GMT
Here is the info regarding the partial hold on their Phase 1 trial:
"On November 5, 2013, we received written notification from the FDA that this phase 1 trial of CUDC-427 had been placed on partial clinical hold following the report of death of a patient who progressed to liver failure approximately one month following the discontinuation of CUDC-427 dosing. In February 2014, we responded to the FDA’s requests for additional information and also submitted an amendment to the current protocol. In March 2014, the FDA completed its review of our complete response submission and determined that it was safe to proceed under the IND and lifted the partial clinical hold on the single agent phase 1 trial for CUDC-427 in patients with advanced relapsed/refractory solid tumors or lymphoma"
Regarding big pps moving events, I'm simply looking for the stock price to appreciate as results from these two Phase 1 trials are reported, and the revenue from Erivedge continues to increase. If Erivedge revenues start to exceed the maximum loan repayment (2 million/quarter) I think it would be a big boost to the share price because not only would they have obviously the $30 million from when they cashed out the royalty stream basically through the loan, but they would have an additional steady revenue stream to fund operations with, which is a nice security blanket and allows them to self sufficiently fund their in house trials.
|
|
|
Post by HeyNow on Jul 15, 2014 13:58:06 GMT
My 1.80 order just executed.
This is my first share purchase of any company for a long while. I've got some redeeming to do with the way ACTC has performed over the last year or so.
|
|
|
Post by JHam on Jul 16, 2014 6:38:08 GMT
Here is the info regarding the partial hold on their Phase 1 trial: "On November 5, 2013, we received written notification from the FDA that this phase 1 trial of CUDC-427 had been placed on partial clinical hold following the report of death of a patient who progressed to liver failure approximately one month following the discontinuation of CUDC-427 dosing. In February 2014, we responded to the FDA’s requests for additional information and also submitted an amendment to the current protocol. In March 2014, the FDA completed its review of our complete response submission and determined that it was safe to proceed under the IND and lifted the partial clinical hold on the single agent phase 1 trial for CUDC-427 in patients with advanced relapsed/refractory solid tumors or lymphoma" Regarding big pps moving events, I'm simply looking for the stock price to appreciate as results from these two Phase 1 trials are reported, and the revenue from Erivedge continues to increase. If Erivedge revenues start to exceed the maximum loan repayment (2 million/quarter) I think it would be a big boost to the share price because not only would they have obviously the $30 million from when they cashed out the royalty stream basically through the loan, but they would have an additional steady revenue stream to fund operations with, which is a nice security blanket and allows them to self sufficiently fund their in house trials. Thanks for the PR link and the breakdown. So it seems like everything is fine with the trial now, people are just still a little spooked? This one is in my radar now and I want to dig in and learn a bit more when I have time. Congrats on getting your first buy in a while. It feels good owning stock of a few different companies.
|
|
|
Post by HeyNow on Jul 16, 2014 13:43:20 GMT
It does feel good to be diversified a bit. That section was just copy-pasted from their quarterly filing. The sp dropped like 50% immediately following that announcement and more in the following weeks so I would think investors were definitely spooked. The stock really didn't/hasn't recovered at all since the trial came back online. In no way do I want to diminish the tragedy of a death, but in late stage cancer trials they are certainly not impossible or even uncommon.
|
|
|
Post by HeyNow on Jul 16, 2014 15:35:00 GMT
www.wkrb13.com/markets/334669/curis-short-interest-up-23-7-in-june-cris/"Shares of Curis (NASDAQ:CRIS) were the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 8,275,495 shares, an increase of 23.7% from the June 13th total of 6,692,521 shares, American Banking & Market News reports. Based on an average trading volume of 2,469,249 shares, the short-interest ratio is presently 3.4 days. Approximately 9.9% of the shares of the stock are short sold."
|
|
|
Post by JHam on Jul 17, 2014 3:43:56 GMT
It does feel good to be diversified a bit. That section was just copy-pasted from their quarterly filing. The sp dropped like 50% immediately following that announcement and more in the following weeks so I would think investors were definitely spooked. The stock really didn't/hasn't recovered at all since the trial came back online. In no way do I want to diminish the tragedy of a death, but in late stage cancer trials they are certainly not impossible or even uncommon. Not to keep using the example of FOLD, but when that stock crumbled after missing primary endpoints, it stayed at it's lows until a) they had good results from a different trial and b) once they were able to prove that missing primary endpoints had to do with trial design and that the treatment was actually very effective (that's what caused the recent spike above $4). So with CRIS I wonder if it is the same in that spooked investors are just hanging around waiting to see that the treatment really works. I agree, that in these trials death unfortunately happens and has nothing to do with whether or not the treatment is effective. CRIS beaten down pretty badly, at pretty much at the 52 week low. That is appealing for someone considering buying. I wish we had a better idea on when we could expect new data on the trial.
|
|
|
Post by HeyNow on Jul 17, 2014 11:17:55 GMT
JHam, here's a list of what could be catalysts in the upcoming months, although tough to know the timing beyond one scheduled presentation (BMO Capital Markets Biotech Corporate Access Day in Boston: July 29, 2014)
The potential near term catalysts for their two wholly owned compounds in phase 1 are, first for CUDC-907: "We expect to complete the dose-escalation phase of this phase 1 trial in the middle of 2014 and initiate enrollment in the expansion cohort(s) in patients with select malignancies in the second half of 2014. In addition to our ongoing phase 1 clinical trial in advanced lymphomas and multiple myeloma patients, we are conducting preclinical studies with CUDC-907 in solid tumor models and expect to initiate additional studies with CUDC-907 in patients with solid tumors later in 2014 or early 2015"
and for CUDC-427 (the one that was halted): We also expect to initiate separate trial with CUDC-427 in combination with standard-of-care chemotherapy regimens including capecitabine later this year.
Now that they have a revenue stream from a marketed drug, I expect quarter over quarter revenue numbers to affect the stock price as well.
|
|
|
Post by selluwud on Jul 31, 2014 17:43:21 GMT
CRIS up 6% today. Going up in advance of quarterly report.
|
|
|
Post by HeyNow on Aug 7, 2014 13:18:51 GMT
|
|
|
Post by JHam on Aug 7, 2014 13:24:31 GMT
You beat me too it. I just saw the earnings report summary. Good stuff. You'd this would give a nice bump today. I still don't own any shares, but congrats to those who do. I have been doing a lot of shuffling around in my portfolio in recent days. CRIS is still on my list and maybe it is time I get more serious in my DD on this one.
|
|
|
Post by JHam on Aug 7, 2014 14:06:05 GMT
I am surprised it is down almost 5% on this news. I guess the market doesn't care about a 40% jump in revenue?
|
|
|
Post by HeyNow on Aug 7, 2014 14:09:06 GMT
It won't be down for long. Market does funny things sometimes I guess
|
|
|
Post by JHam on Aug 7, 2014 14:25:27 GMT
It won't be down for long. Market does funny things sometimes I guess It would be nice if you are right. I just wrote up some questions before I saw this post, but I'll go ahead and ask anyway. I am interested in this company. Specifically? I like the cash situation, medium/low share count, arena they are working in, fact that they have partnerships/license deals already inked, and that they are in the Nasdaq. Here are my questions: Since it doesn't seem like the market gives a sh*t about beating estimates, increased revenue, and a $3M up front payment from Roche, do you think that any news/developments from Phase I can cause a spark? The market cap seems a little high for a company in Phase I. Even with a revenue stream coming in, is that why this one doesn't want to move on pretty good news? Do you think there is room to grow even on the other catalysts you stated, specifically Phase I news? Also, do you know what the current cash burn rate is? If they had $70M in July and estimate $50M by the end of the year, that would come out to about $10M a quarter correct? Sorry for all the questions.
|
|
|
Post by selluwud on Aug 7, 2014 14:38:31 GMT
It won't be down for long. Market does funny things sometimes I guess I think it was the basic trader buying on the rumor and then selling when the news did come out. I feel like it will hold somewhere in the 1.80's to 1.90's until some type of news is made public again.
|
|